Asthma & Copd Market Worth Over $33 Billion In 2016’ Says Visiongain Report

30 August 2016
Pharma

Visiongain’s new report the Asthma & COPD Market Report 2016-2026 : Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs
indicates that the global Asthma & COPD Market will see over $33.2bn in revenue in 2016.

The lead analyst of the report said: “The asthma and COPD therapies market is becoming more complex. The entry of generic versions of best selling products will lead to slow growth for the next few years, while market leaders continue to innovate with more advanced inhaler devices and novel combination therapies. These products will demand high prices and result in significant returns for the companies that have developed them. There is increasingly greater recognition of different patient phenotypes in asthma and COPD. This is especially the case in severe asthma, as new monoclonal antibodies target specific inflammatory mediators in subgroups of patients. This increased personalisation of treatment and increase in the use of biologics will drive growth, which will be restrained by the entry of generic versions of current market-leading drugs over the next few years”

The 313 page report contains 248 tables, charts and graphs that add visual analysis in order to explain developing trends within the Asthma & COPD market. Visiongain provides revenue forecasts for the period 2016-2026 for the 3 leading Asthma & COPD submarkets, namely Bronchodilator Monotherapy, Anti-Inflammatory Drugs and Combination Drugs. The report also includes forecasts for the corticosteroids market and performance assessments for anti-leukotrienes and monoclonal antibodies, Short-acting beta2-agonists (SABAs), Long-acting beta2-agonists (LABAs) and anticholinergics.

The 313 page report offers market forecasts and analysis for 12 leading national markets and the rest of the world market. In addition, the report contains a dedicated leading companies’ chapter covering more than 6 companies leading the field in asthma & COPD drug therapies.

The Asthma & COPD Market Report 2016-2026: Forecasts for Bronchodilator Monotherapy (Including Anticholinergics, SABAs and LABAs), Anti-Inflammatory Drugs (Including Corticosteroids, Anti-Leukotrienes and Monoclonal Antibodies) and Combination Drugs report will be of value to anyone who wants to better understand the asthma & COPD market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of asthma & COPD industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever